The most extensively studied compounds are exenatide (Byetta [Amylin Pharmaceuticals, San Diego, CA], which has been approved by the US Food and Drug Administration [FDA] for the treatment of type 2 diabetes), liraglutide (Victoza [Novo Nordisk, Princeton, NJ], which has been submitted to the FDA for approval), sitaglitptin (Januvia [Abbott Laboratories, Abbott Park, IL], which has been approved by the FDA for type 2 diabetes), and vildagliptin (Galvus [Novo Nordisk, Princeton, NJ], which has been submitted to FDA)
More than 90% of people with type 1 diabetes and 50-60% of those with type 2 diabetes develop this condition, in which high blood sugar levels damage blood vessels in the light-sensitive tissue at the back of the eye
The compound's protective properties allow a meaningful percentage to survive the digestive journey and reach systemic circulation
BPC157 :New anti-inflammatory peptide | Seven Hills Medical Centr
Severity of seizures was assessed using the Chalfont seizure severity scale (CSSS) 18
doi:10.2165/00063030-199912020-00007 Raun K, Hansen B, Johansen N, Thogersen H, Madsen K, Ankersen M, Andersen P